Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
- Extraordinary efficacy of a HER2-targeting Trastuzumab-ATAC in the treatment of Triple-Negative Breast Cancer (TNBC) with low HER2 expression and hemizygous deletion of chromosome 17p in preclinical models
- Induction of immunogenic cell death by an HER2-ATAC – Synergistic and increased efficacy in combination with checkpoint inhibitors
Heidelberg Pharma AG today announced that new study results on the Antibody Targeted Amanitin Conjugate (ATAC) technology have been published in the journal Science Translational Medicine, in a joint report by a research group at the School of Medicine, Indiana University, Indianapolis, IN, USA, and scientists of Heidelberg Pharma.